Core Viewpoint - Shanghai Hengrunda Biotechnology Co., Ltd. has announced a commercialization partnership with China Resources Double Crane Pharmaceutical Co., Ltd. for the exclusive national agency rights of Renikiorunsai Injection (Hengkailai®) [1] Group 1: Company Collaboration - The partnership allows China Resources Double Crane to exclusively distribute Hengkailai®, which is China's first fully independently developed CD19 CAR-T product targeting relapsed or refractory large B-cell lymphoma (r/r LBCL) [1] - This collaboration is seen as a strong practice of social responsibility by China Resources Double Crane and highlights the mission of innovative biopharmaceutical private enterprises focusing on clinical needs and deepening innovative therapies [1] Group 2: Industry Implications - The cooperation represents a new exploration of collaborative development models in the field of tumor immunotherapy in China [1]